Immunocore Ltd

ACTIVE

2273 Research Blvd, Rockville, Maryland, United Kingdomwww.immunocore.comPublic251–500 employeesEstablished: 2008-01-01$1.8B

Part of Immunocore

Clinical Trials

9 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

78.3%

Phase 2

8.7%

Phase 3

8.7%

Trial Status Distribution

Active, not recruiting

39.1%

Available

4.3%

Completed

13.0%

Recruiting

21.7%

Terminated

8.7%

Withdrawn

13.0%

Clinical Trials

Trials sponsored by this organization (23)

Study of IMC-P115C in Advanced PRAME-Positive Cancers

Phase 1

Recruiting

interventional

Nov 2024140 participants

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Phase 3

Recruiting

interventional

Jun 2024680 participants

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Phase 1

Recruiting

interventional

Jan 2024600 participants

Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic HBV infectio

Phase 1

Active, not recruiting

interventional

Jan 2023108 participants

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3

Recruiting

interventional

Dec 2022540 participants

Phase 1/2 study of IMC-I109V in non-cirrhotic HBeAg-negative chronic HBV infectio

Phase 1

Active, not recruiting

Apr 202280 participants

A study to test if IMCgp100 in combination with Durvalumab or Tremelimumab or the combination of Durvalumab and Tremelimumab compared to IMCgp100 alone is safe and effective in patients with advanced skin cancer.

Phase 1

Active, not recruiting

Jun 2021224 participants

A clinical trial comparing the safety and activity of IMCgp100 to Investigator's Choice. This study will only take place in patients who have a particular type (HLA-A*0201) of the uveal melanoma (a cancer which started and then spread from the coloured cells of the eye).

Phase 1

Active, not recruiting

Jun 2021327 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations